Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Alle Kategorien

VAT gewinnt den Supplier Excellence Award 2019 von LAM Research » Report
ABB begins construction of new robotics factory in Shanghai » Report
World Gold Council: World Gold Council führt Grundsätze für einen verantwortungsbewussten Goldabbau ein » World Gold Council
Peach Property: Kauf von über 3.650 Wohnungen in Deutschland – Wert des Bestandsportfolios steigt auf rd. CHF 1,1 Mrd » Peach Property
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum » Report
GROUPE ROMANDE ENERGIE » Report
Dufry signs new contract and expands its operations; in Florianópolis International Airport » Report
Newron reports half-year 2019 results » Report
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy » Report
The transHuman Code Bestseller and Ethics in AI Debated at the 2019 Zermatt Summit » Report
Newron berichtet über das Halbjahresergebnis 2019 » Report
dormakaba 2018/19 financial results: Further increase in profitability, higher dividend proposed again » Report
dormakaba Geschäftsergebnisse 2018/19: Weitere Steigerung der Profitabilität, erneut höhere Dividende beantragt » Report
SGS Launches New Service for International Type Approval (ITA) Restricted Substance Compliance » Report
ObsEva announces new composition of its Executive Committee » Report
Flughafen Zürich: Verkehrsstatistik vom August 2019 » Report
Key traffic figures Zurich Airport August 2019 In August » Report
Kudelski Security named a Major Player in the IDC MarketScape: U.S. Emerging Managed Security Services » Report
Idorsia Ltd: Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis » Report
Idorsia Ltd: Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis » Report